Amorette Barber, Ph.D.

Affiliations: 
2009 Immunology and Microbiology Dartmouth College, Hanover, NH, United States 
Area:
Cell Biology, Molecular Biology
Google:
"Amorette Barber"

Parents

Sign in to add mentor
Charles L. Sentman grad student 2009 Dartmouth
 (Chimeric NKG2D receptor expressing T cells as immunotherapy for cancer.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Spear P, Barber A, Sentman CL. (2013) Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology. 2: e23564
Spear P, Barber A, Rynda-Apple A, et al. (2013) NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunology and Cell Biology. 91: 435-40
Spear P, Barber A, Rynda-Apple A, et al. (2012) Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. Journal of Immunology (Baltimore, Md. : 1950). 188: 6389-98
Barber A, Sentman CL. (2011) NKG2D receptor regulates human effector T-cell cytokine production. Blood. 117: 6571-81
Barber A, Meehan KR, Sentman CL. (2011) Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Therapy. 18: 509-16
Barber A, Rynda A, Sentman CL. (2009) Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 183: 6939-47
Barber A, Sentman CL. (2009) Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. Journal of Immunology (Baltimore, Md. : 1950). 183: 2365-72
Cubillos-Ruiz JR, Engle X, Scarlett UK, et al. (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. The Journal of Clinical Investigation. 119: 2231-44
Barber A, Zhang T, Megli CJ, et al. (2008) Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Experimental Hematology. 36: 1318-28
Barber A, Zhang T, Sentman CL. (2008) Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. Journal of Immunology (Baltimore, Md. : 1950). 180: 72-8
See more...